In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
REGULATORY
Japan Approves Pfizer’s Omicron XBB.1.5 Vaccine, Moderna’s Still under Review
The Japanese government on September 1 granted special approval for Pfizer/BioNTech’s updated monovalent COVID-19 vaccines adapted to the XBB.1.5 subvariant of Omicron. The new jabs are set for a rollout on September 20, targeting all generations. The government has already…
To read the full story
Related Article
- Pfizer Rolls Out Single-Dose Version of COVID-19 Vaccine in Japan
May 20, 2024
- Japan to Buy 10 Million More Doses of Pfizer/Moderna COVID Jabs
October 19, 2023
- Japan Agrees to Buy Extra 10 Million Doses of Pfizer COVID Vaccine
September 27, 2023
- Japan Launches Fall COVID-19 Vaccination Campaign
September 21, 2023
- Japan Panel OKs Use of Pfizer’s XBB.1.5 Jab for Fall Vaccination Campaign
September 11, 2023
- Japan Panel OKs Rollout of XBB.1.5-Based COVID Vaccines on Sept. 20
August 10, 2023
- Moderna Japan’s XBB-Based COVID Jab Actually Filed for Age 6 and Up
August 3, 2023
- Pfizer, Moderna File Updated COVID-19 Vaccines in Japan
July 7, 2023
REGULATORY
- PMDA-Led Inspections Will Help Straighten Up Generic Makers: MHLW Councilor
September 6, 2024
- MOF Intent on Expanding Scope of Off-Year Revision in 2025: Budget Examiner
September 6, 2024
- Trodelvy Up for Japan Panel Review on Sept. 12, Meiji COVID Jab on Agenda Too
September 6, 2024
- Japan to Prepare Fact Sheets on RSV Vaccine, Antibody
September 5, 2024
- Japan Poised to Launch FIH Trial System in FY2029 to Attract Global Seeds
September 5, 2024
An increasing number of companies in Japan are showing an eagerness to snatch up “drug loss” assets. As of this…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…